The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial

Marc A. Pfeffer; Michael Domanski; Joel Verter; Mark Dunlap; Greg C. Flaker; Bernard Gersh; Judith Hsia; A. David Goldberg; Marian C. Limacher; Aldo P. Maggioni; Yves Rosenberg; Jean Lucien Rouleau; J. Wayne Warnica; Alan G. Wasserman; Eugene Braunwald

doi:10.1067/mhj.2001.117603

The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial

Marc A. Pfeffer
, Michael Domanski
, Joel Verter
, Mark Dunlap
, Greg C. Flaker
, Bernard Gersh
, Judith Hsia
, A. David Goldberg
, Marian C. Limacher
, Aldo P. Maggioni
, Yves Rosenberg
, Jean Lucien Rouleau
, J. Wayne Warnica
, Alan G. Wasserman
, Eugene Braunwald

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Original language	English
Pages (from-to)	375-377
Number of pages	3
Journal	American Heart Journal
Volume	142
Issue number	3
DOIs	https://doi.org/10.1067/mhj.2001.117603
State	Published - 2001
Externally published	Yes

Access to Document

10.1067/mhj.2001.117603

Cite this

Pfeffer, M. A., Domanski, M., Verter, J., Dunlap, M., Flaker, G. C., Gersh, B., Hsia, J., Goldberg, A. D., Limacher, M. C., Maggioni, A. P., Rosenberg, Y., Rouleau, J. L., Warnica, J. W., Wasserman, A. G., & Braunwald, E. (2001). The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial. American Heart Journal, 142(3), 375-377. https://doi.org/10.1067/mhj.2001.117603

@article{6b5c7bfa5edd4c3da0945b6c99b82d78,

title = "The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial",

author = "Pfeffer, \{Marc A.\} and Michael Domanski and Joel Verter and Mark Dunlap and Flaker, \{Greg C.\} and Bernard Gersh and Judith Hsia and Goldberg, \{A. David\} and Limacher, \{Marian C.\} and Maggioni, \{Aldo P.\} and Yves Rosenberg and Rouleau, \{Jean Lucien\} and Warnica, \{J. Wayne\} and Wasserman, \{Alan G.\} and Eugene Braunwald",

note = "Funding Information: The specific ACE inhibitor tested was chosen by the NHLBI in conjunction with the PEACE Executive Committee. The requirements were that the agent had to be previously evaluated and proved to be associated with a mortality benefit in a post–myocardial infarction (MI) cohort so that a known successful dosage could be used in PEACE. The ACE inhibitor trandolapril was selected. When used in a once-a-day target dosage, it had been shown to reduce mortality in patients with post-MI left ventricular dysfunction in the Trandolapril Cardiac Evaluation (TRACE) study. 6 PEACE is funded by the NHLBI. The manufacturer of trandolapril, Knoll AG, supplies the active drug and matching placebo to the study as well as some support for ancillary studies. ",

year = "2001",

doi = "10.1067/mhj.2001.117603",

language = "English",

volume = "142",

pages = "375--377",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

number = "3",

}

Pfeffer, MA, Domanski, M, Verter, J, Dunlap, M, Flaker, GC, Gersh, B, Hsia, J, Goldberg, AD, Limacher, MC, Maggioni, AP, Rosenberg, Y, Rouleau, JL, Warnica, JW, Wasserman, AG & Braunwald, E 2001, 'The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial', American Heart Journal, vol. 142, no. 3, pp. 375-377. https://doi.org/10.1067/mhj.2001.117603

TY - JOUR

T1 - The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial

AU - Pfeffer, Marc A.

AU - Domanski, Michael

AU - Verter, Joel

AU - Dunlap, Mark

AU - Flaker, Greg C.

AU - Gersh, Bernard

AU - Hsia, Judith

AU - Goldberg, A. David

AU - Limacher, Marian C.

AU - Maggioni, Aldo P.

AU - Rosenberg, Yves

AU - Rouleau, Jean Lucien

AU - Warnica, J. Wayne

AU - Wasserman, Alan G.

AU - Braunwald, Eugene

N1 - Funding Information: The specific ACE inhibitor tested was chosen by the NHLBI in conjunction with the PEACE Executive Committee. The requirements were that the agent had to be previously evaluated and proved to be associated with a mortality benefit in a post–myocardial infarction (MI) cohort so that a known successful dosage could be used in PEACE. The ACE inhibitor trandolapril was selected. When used in a once-a-day target dosage, it had been shown to reduce mortality in patients with post-MI left ventricular dysfunction in the Trandolapril Cardiac Evaluation (TRACE) study. 6 PEACE is funded by the NHLBI. The manufacturer of trandolapril, Knoll AG, supplies the active drug and matching placebo to the study as well as some support for ancillary studies.

PY - 2001

Y1 - 2001

UR - https://www.scopus.com/pages/publications/17944364938

U2 - 10.1067/mhj.2001.117603

DO - 10.1067/mhj.2001.117603

M3 - Article

C2 - 11526345

AN - SCOPUS:17944364938

SN - 0002-8703

VL - 142

SP - 375

EP - 377

JO - American Heart Journal

JF - American Heart Journal

IS - 3

ER -